Pharming Reports on Shareholders Meeting

Pharming Reports on Shareholders Meeting
LEIDEN, NETHERLANDS–(Marketwire – May 28, 2010) – Biotech company Pharming Group NV (”Pharming” or “the Company”) (NYSE Euronext: PHARM) announces that all items on the agenda of today’s Annual General Meeting of Shareholders (AGM) have been approved by the Shareholders.

Read more on Marketwire

Pharming submits D180 response for Rhucin MAA to EMA without clock stop

Pharming submits D180 response for Rhucin MAA to EMA without clock stop
LEIDEN, NETHERLANDS–(Marketwire – 05/25/10) – Biotech company Pharming Group NV (”Pharming” or “the Company”) (NYSE Euronext: PHARM) announces that it has submitted its response to the Day 180 List of Outstanding Issues (LoOI) to the Committee for Medicinal Products for Human Use (CHMP) in regard to its European Marketing Authorization Application (MAA) for Rhucin without an additional clock …

Read more on Marketwire via Yahoo! Finance

Pharming provides update on outstanding shares

Pharming provides update on outstanding shares
LEIDEN, NETHERLANDS–(Marketwire – 05/17/10) – Biotech company Pharming Group NV (”Pharming”) (NYSE Euronext: PHARM) today provided an update on its outstanding number of shares. As result of various conversion notices, totalling EUR2.0 million, from the January 2010 EUR7.5 million Private Bonds, Pharming issued a total amount 6,256,028 ordinary shares in return for these conversions. These …

Read more on Marketwire via Yahoo! Finance

D-Pharm Receives Agreement Letter On Special Protocol Assessment For DP-b99 Study – A Pivotal Phase III Trial In Acute …

D-Pharm Receives Agreement Letter On Special Protocol Assessment For DP-b99 Study – A Pivotal Phase III Trial In Acute …
D-Pharm Ltd (DPRM: TASE) announced that it has reached an agreement with the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) procedure for a pivotal phase 3 trial (MACSI) of its neuroprotective agent DP-b99 in acute ischemic stroke patients. The SPA agreement letter indicates that “the design and planned analysis of the study adequately address the objectives …

Read more on Medical News Today

Pharming’s C1 Inhibitor Effective in Preventing AMR in Animal Model of Transplant Rejection

Pharming’s C1 Inhibitor Effective in Preventing AMR in Animal Model of Transplant Rejection
LEIDEN, NETHERLANDS–(Marketwire – April 1, 2010) – Biotech company Pharming Group NV (”Pharming” or “the Company”) (NYSE Euronext: PHARM) announced today publication of preclinical evidence that its recombinant human C1 inhibitor (rhC1INH) was effective in a primate model in preventing antibody-mediated rejection (AMR) following kidney transplantation.

Read more on Marketwire

Next Page »